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CONSPECTUS
Light-responsive agents offer the promise of targeted therapy, whose benefits include (i) prolonged 
action at the target site, (ii) overall reduced systemic dosage, (iii) reduced adverse effects, and (iv) 
localized delivery of multiple agents. Although photoactivated prodrugs have been reported, these 
species generally require short wavelengths (<450 nm) for activation. However, maximal tissue 
penetrance by light occurs within the “optical window of tissue” (600–900 nm), well beyond the 
wavelength range of most existing photocleavable functional groups. Furthermore, since multidrug 
therapy holds promise for the treatment of complex diseases, from cancer to neurological 
disorders, controlling the action of multiple drugs via wavelength modulation would take 
advantage of a property that is unique to light. However, discrimination between existing 
photoresponsive moieties has thus far proven to be limited.
We have developed a vitamin B12/light-facilitated strategy for controlling drug action using red, 
far-red, and NIR light. The technology is based on a light-triggered reaction displayed by a subset 
of B12 derivatives: alkyl-cob(III)alamins suffer photohomolysis of the C–Co(III) bond. The C–
Co(III) bond is weak (<30 kcal/mol), and therefore all wavelengths absorbed by the corrin ring 
(330–580 nm) induce photocleavage. In addition, by appending fluorophores to the corrin ring, 
long wavelength light (>600 nm) is readily captured and used to separate the Co-appended ligand 
(e.g., a drug) from B12. Consequently, it is now feasible to preassign the wavelength of homolysis 
by simply installing a fluorescent antenna with the desired photophysical properties. The 
wavelength malleability inherent within this strategy has been used to construct photoresponsive 
compounds that launch different drugs by simply modulating the wavelength of illumination. In 
addition, these phototherapeutics have been installed on the surface and interior of cells, such as 
erythrocytes or neural stem cells, and released upon expoure to the appropriate wavelength. We 
have shown that cytotoxic agents, such as doxorubicin, anti-inflammatories, such as 
dexamethasone, and anti- and pro-vascular agents are readily released from cellular vehicles as 
biologically active agents. We have also demonstrated that the concept of “optical window of 
tissue” phototherapeutics is not just limited to prodrugs. For example, stem cells have received 
considerable attention in the area of regenerative medicine. Hydrogels serve as scaffolds for stem 
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cell growth and differentiation. We have shown that the formation of hydrogels can be triggered, in 
the presence of cells, using appropriately designed alkyl-cob(III)alamins and long wavelength 
light. The potential applications of phototherapeutics are broad and include drug delivery for a 
variety of indications, tissue engineering, and surgery.
Graphical abstract
1. INTRODUCTION
Light has been used in conjunction with photoresponsive agents1–4 to control the 
biochemistry of cells, manipulate the behavior of organisms, and treat a variety of 
pathological conditions. The applications of “phototherapeutics” are broad, including cancer 
therapy, tissue engineering, and surgery. Indeed, the opportunities associated with 
phototherapeutics have received considerable attention in the scientific literature as well as 
the popular media5 and culture.6 For example, an externally applied beam of light to perform 
surgery, as opposed to a scalpel, enjoys an array of potential advantages including (1) 
reduced exposure to infectious disease, (2) reduced reliance on anesthesia, (3) quicker 
recovery time, and (4) pinpoint accuracy along with the intriguing possibility of performing 
different procedures with different wavelengths of light (Figure 1). In this, and many other 
examples, light serves to trigger the action of dormant photoresponsive species at the site of 
illumination.
A wide variety of light-responsive bioagents have been described, including biological/
biochemical sensors, nucleic acids, enzyme substrates and inhibitors, proteins 
(optogenetics), and triggers for the generation of biomaterials.1–4 Most light-responsive 
species are prepared by covalently modifying an essential-for-activity functional group on 
the compound of interest.3 The modifying agent (often, but misleadingly, referred to as a 
“caging” agent) is a photocleavable moiety designed to furnish a biologically inactive 
species that can be restored to full activity upon photolysis. Although the simplicity of this 
idea is compelling, its application to the fields of biology and biomedicine faces a number of 
daunting hurdles. The most widely recognized challenge is that short wavelengths (<600 
nm) do not readily penetrate the epidermis due to the presence of common biological 
chromophores, specifically melanin and hemoglobin. Furthermore, wavelengths beyond 950 
nm are strongly absorbed by water. The sweet spot of tissue penetrance, namely, between 
650–900 nm, is often referred to as the optical window of tissue. Unfortunately, the 
overwhelming majority of light-cleavable moieties suffer photolysis with UV or short visible 
light (<450 nm). One strategy to overcome this limitation is the construction red-shifted 
versions of photocleavable groups. However, this results in dramatically reduced photolytic 
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quantum yields.7 The latter highlights another significant challenge, namely, “red and NIR 
photons have relatively low energy, limiting the range of processes they can initiate”.2 
Nonetheless, red, far-red, and NIR wavelengths are tissue penetrating (up to 10 cm),8 are 
less subject to light scattering than shorter wavelengths, and offer a broad spectral range that 
could potentially be used to orthogonally control multiple photoagents.9 Consequently, a call 
has been put forth to extend “the wavelength coverage for activation… with visible and 
infrared light and [improve] the absorption properties for wavelength-selective, orthogonal 
activation”.2 A similar appeal has been made in the field of optogenetics.10
What kind of “processes” are triggered by red and near-IR photons? Two photon technology 
and upconverting nanoparticles transform the low energies of long wavelength photons into 
a form that drives high energy-requiring processes. Unfortunately, these approaches have 
their own unique set of limitations.11,12 Are there relatively weak covalent bonds that might 
be directly subject to photolysis by long wavelengths? One possibility is water-stable 
organometallic species. Indeed, a rich array of inorganic and organometallic 
photoactivatable systems has been described, including photodynamic agents (1O2 
generators)13,14 and carriers of small gas molecules (CO,15 NO16). In addition, a few 
examples of the light-mediated release of larger bioactive compounds have also been 
reported, such as γ-amino butyric acid and glutamic acid.14,17 However, like their 
completely organic light-responsive brethren, these organometallic species generally require 
wavelengths shorter than the optical window of tissue to trigger photorelease (longer 
wavelength photolysis has been achieved via two-photon excitation18).
The photohomolysis of the C–Co bond in alkyl-cob(III)-alamins, 1 (alkyl-Cbls; R = CN, 
CH3, and adenosyl for vitamin B12), was noted a half-century ago (Scheme 1).19–22 The 
alkyl radical and Co(II) photoproducts (2) are identical to the intermediates formed in the 
enzyme-catalyzed reactions and thus offers a relatively simple means to model B12-
dependent transformations. In addition, the C–Co bond is weak (<30 kcal/mol), and the 
energies supplied by any of the wavelengths absorbed by the corrin ring system (330–560 
nm) are sufficient to induce cleavage with high quantum yields.23–26 We viewed 
multiwavelength-induced bond cleavage of alkyl-Cbls as a unique opportunity, one that we 
thought could be commandeered for biological and biomedical applications.
2. EXPANSION OF THE PHOTOCHEMICAL TOOLKIT USING ALKYL-Cbls
The o-nitrobenzyl group, which is sensitive to 330–360 nm, is the work horse of 
photomodulated bioreagents.27 However, there exists intense interest in expanding the 
toolkit of photoresponsive compounds to allow for the differential activation of more than 
one compound. For example, coumarin 4-ylmethyl modified bioagents2,28–33 are sensitive to 
longer wavelengths of light (400–450 nm) than o-nitrobenzyl substituted derivatives. We 
examined the potential utility of alkyl-Cbls as photoresponsive compounds by first preparing 
the derivative TAM-Cbl, 3 (Chart 1), which contains an appended TAM fluorophore 
moiety.34 Cbl quenches the fluorescence of a variety of fluorophores.35–38 We reasoned that 
this property could be useful since an increase in fluorescence would serve as a barometer of 
successful C–Co bond photohomolysis if the fluorophore were positioned on the bond 
undergoing photolysis.34,39–43 The ability to photolyze 3 in a wavelength selective fashion 
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was assessed in the presence of UV-responsive 4 and blue-responsive 5 (Chart 1). These 
agents contain a mitochondrial localization sequence, which promotes mitochondrial 
association and was useful in visualizing the photocleavage event under biologically relevant 
conditions.34 As anticipated, the Cbl conjugate 3 undergoes photohomolysis at 560 nm, a 
wavelength that has no effect on 4 or 5, whereas 4 experiences photolysis at 440 nm, a 
wavelength that has no impact on 3. Finally, the latter is only susceptible to photolysis at 360 
nm. Using this relatively simple set of compounds, we demonstrated the feasibility of 
issuing “commands” to individual entities via wavelength modulation, thereby 
demonstrating the potential of manipulating multiple, yet separate, biological processes 
using light alone.34 However, reliance upon the nitrobenzyl and coumarin moieties limits 
application to simple systems, such as cell culture. Furthermore, although 3 represents a 
profound 100 nm+ step in the right direction (560 nm versus 440 nm for 4 and 360 nm for 
5), it still falls far short of breaching the optical window of tissue (650–900 nm).
Light-responsive biological agents are commonly prepared via covalent modification of a 
functional group essential for biological activity.2,3 The substituted functionality is revealed 
upon illumination, thereby restoring activity to the molecule in question. Alcohols, amines, 
and carboxylates are common sites for substitution by photocleavable moieties. By contrast, 
we found that photohomolysis of RCH2-Co(III)Cbl primarily generates the alkyl, RCH3, 
product under cell culture conditions.44 It struck us as unlikely that attaching Cbl to 
“essential” methyl groups in biologically active compounds would serve as a general method 
for preparing light-activatable species. Initially, we wondered whether the steric bulk of the 
corrin ring might be sufficient to provide biological camouflage, precluding the interaction 
of inhibitors, activators, or sensors with their biological targets. For example, we prepared 
the Cbl modified cAMP derivative 6 (Chart 2) and examined its ability to activate the PKA 
protein kinase in the dark and following illumination at 530 nm.43 However, we found that 
the presence of the corrin ring fails to completely block biological activity. Although the 
“steric-bulk” strategy may ultimately find application in some systems, we sought a more 
reliable strategy for creating light-responsive Cbl-based agents.
We have previously demonstrated that molecules can be biologically camouflaged by 
controlling their cellular location.40 Based on earlier reports, we anticipated that Cbl 
derivatives would be taken up and retained by endosomes,45,46 thereby offering an attractive 
means of keeping the reagent away from its intracellular biological target. Subsequent 
illumination should detach the cell-permeable cargo from the Cbl moiety, enabling escape 
from the endosomal depot. Our initial studies employed the BODIPY–Cbl conjugate 7 
(Chart 2). The unattached BODIPY moiety freely enters cells and associates with 
mitochondria.47,48 By contrast, the conjugate 7 enters cells by receptor-mediated 
endocytosis and is retained in endosomes. Subsequent photolysis at 650 nm induces 
migration of the BODIPY fluorophore from endosomes to mitochondria (Figure 2).43 The 
use of Cbl as a membrane impermeant agent is not just limited to BODIPY. We also 
examined the effect of the cAMP derivative 6 on cell morphology prior to and following 
illumination. cAMP promotes significant morphological changes in cells, including loss of 
stress fibers and cell rounding. cAMP–Cbl 6 has no effect on cellular morphology in the 
absence of light. By contrast, illumination (530 nm) induces the expected loss in cellular 
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stress fibers as well as cell shrinking and rounding (Figure 3). In an analogous vein, we 
synthesized Dox–Cbl 8 (Chart 2) and examined its cytotoxicity in HeLa cells.43 Dox is a 
powerful anticancer agent that, upon entering the nucleus, intercalates in DNA and thereby 
inhibits the progression of topoisomerase II. However, Dox’s severe cardiotoxicity is 
responsible for the intense interest in developing tumor-selective delivery strategies.49,50 As 
expected, cells simply incubated with 8 display no loss in viability.43 However, a light-dose-
dependent increase in cell death is observed upon illumination (530 nm) in the presence of 
8. The photorelease of cAMP from 6 and Dox from 8 occurs at a wavelength (530 nm) 
absorbed Cbl. By contrast, 650 nm triggers BODIPY–Cbl 7 photolysis, which is well 
beyond the wavelength range of the corrin ring.
3. EXPANSION OF THE PHOTOCHEMICAL TOOLKIT INTO THE OPTICAL 
WINDOW OF TISSUE
The C–Co bond in alkyl-Cbl derivatives is weak (<30 kcal mol−1),20,25 and a back-of-the-
envelope calculation suggests that wavelengths as long as 1000 nm might be sufficient to 
induce photohomolysis. Unfortunately, since Cbl only absorbs out to 560 nm, access to 
biomedically relevant wavelengths in the red, far-red, and near IR is, on first glance, simply 
not feasible. However, since the BODIPY derivative 7 undergoes photohomolysis at a 
wavelength (650 nm) beyond Cbl’s reach, we wondered whether fluorophores could act as 
antennas, capturing wavelengths that are otherwise invisible to the corrin ring system.
A series of alkyl-Cbl derivatives containing appended long wavelength fluorophores were 
prepared including SulfoCy5 (λex 647 nm, 9), AlexaFluor700 (λex 702 nm, 10), Atto725 
(λex 730 nm, 11), and DyLight800 (λex 777 nm, 12) (Chart 3).43 In all cases, the 
fluorophore–Cbl conjugates undergo photohomolysis at wavelengths uniquely absorbed by 
the fluorophore. For example, we subjected a mixture of four photoresponsive compounds, 
each with distinct wavelength excitation profiles, to sequential illumination at 777, 700, 646, 
and 546 nm to obtain exquisitely controlled sequential homolysis of 12, 11, 10, and 9. 
Furthermore, since the excitation spectra of 12 and 10 are nonoverlapping beyond 600 nm, 
these compounds can be selectively photolyzed without resorting to a specific illumination 
sequence.43 However, the position occupied by the antennas in 9–12 is the photocleavable 
site, a position that we intended to reserve for drugs. Fortunately, the ribose ring hydroxyl 
(highlighted in red in 1) is readily modified, and this functional group serves as an ideal 
location to position the antenna. In a fashion analogous to 9–12, we prepared a family of 
long wavelength photoresponsive analogs of adenosyl-Cbl-fluorophore 13.43 Once again, the 
desired photocleavable wavelength (560–800 nm) is easily preassigned by simply installing 
the proper red, far-red, or NIR fluorescent antenna. As a side note, despite the structural 
complexity of these Cbl derivatives (as well as those described below), Cbl–fluorophore/
drug conjugates are easily accessible in a few straightforward steps from readily available 
starting material and are stable at room temperature. We do take care to work under muted 
(indirect) lighting conditions that are nonetheless visually safe for detailed laboratory work.
Do long wavelength responsive Cbls recognize deep tissue penetrating light under 
conditions that are otherwise challenging for shorter wavelengths? A dermal model, which 
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mimics both various skin tones and the light scattering effects of tissue, was used to address 
this question.51 The concentration of melanin in this model is easily varied to simulate a 
variety of skin types from very pale (Fitzpatrick types I–II) to very dark (Fitzpatrick types 
V–VI). We illuminated, using the dermal tissue models as filters, unlabeled (14) and Cy5-
labeled (15) ethyl-Cbl derivatives (Chart 4). As anticipated, in the absence of any skin type 
filter, both agents are rapidly photolyzed (confirmed by absorbance spectrometry and 
LC/MS) upon illumination at the appropriate wavelengths. However, introduction of even 
the palest Fitzpatrick level I–II model as a filter completely prevents the 520-nm-mediated 
photolysis of 14. By contrast, 660 nm illumination through either the Fitzpatrick level I–II 
filter or its darker III–IV counterpart photolyzes 15. Even in the presence of the darkest skin 
type (Fitzpatrick type V–VI), red light photolysis proceeds at only a slightly diminished 
pace. These results confirm the advantages of long wavelength responsive species as agents 
for mediating biochemical processes in tissue.
4. LONG WAVELENGTH TRIGGERED DRUG RELEASE FROM ALKYL-Cbls
Photodynamic therapy (PDT) is used to treat a wide variety of conditions, including 
cancer.52 PDT employs photosensitizers that are selectively retained by the target tissue. 
Following sensitizer uptake, spatially focused illumination generates cytotoxic reactive 
oxygen species at the site of application.8 Despite the decades long effort in this field, PDT 
primarily remains a cytotoxic therapy, albeit one with undeniable clinical success. Is it 
possible to take full advantage of light’s extraordinary attributes to dramatically expand its 
biomedical applications? Can anti-inflammatories be selectively delivered to an arthritic 
knee, clotting agents to a hemorrhaging artery, or protein kinase inhibitors to a tumor? Can 
multiple drugs be applied to a diseased site in a specific sequence via wavelength 
modulation? We felt that affirmative answers to these questions would require a more robust 
delivery system than simple endosomal-mediated uptake as depicted in Figures 2 and 3. One 
obvious possibility is the use of nanoparticles as carriers of phototherapeutics. However, we 
decided, for our initial studies, to take advantage of the biological longevity and 
biocompatibility inherent with cell-based vehicles. For example, erythrocytes have a four-
month life span, have a comparatively large size and thus potentially large loading capacity, 
and are easy to retrieve from and reintroduce into the patient. Finally, although erythrocytes 
have been described as the “the champions of drug delivery”, the use of red blood cells as 
therapeutic carriers has been limited by the inability to control drug release on command (a 
limitation potentially addressable with light).53
An assortment of lipidated (C18) conjugates of Cbl–drugs and fluorophores were prepared, 
with the expectation that the surface of erythrocytes would mediate the assembly of 
functional antenna/drug–Cbl arrays (Figure 4).44 We decided to focus on anti-inflammatory 
drugs based on their role in treating arthritis. Long-term use of anti-inflammatory agents can 
and does result in moderate to severe side effects. Not surprisingly, there is intense interest 
in targeting antiinflammatories to the site of inflammation in order to improve their 
therapeutic windows.54,55 The anti-inflammatory drugs methotrexate (Mtx), colchicine 
(Col), and dexamethasone (Dex) were conjugated to lipidated Cbls (16, 17, and 18, 
respectively; Chart 5). These conjugates were paired with different lipidated fluorophores 
(19–22; Chart 5) for assembly on the surface of blood cells. In all cases, 
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phototherapeuticloaded erythrocytes were subsequently incubated with target adherent cell 
lines in the dark. Drug release from erythrocytes is only observed upon illumination at the 
proper wavelength. For example, Dex is released from RBCs loaded with 18/19 upon 
illumination at the wavelength (660 nm) recognized by Cy5. The released Dex induces the 
anticipated response in the target cells (Figure 5a,b). We found that it is quite 
straightforward to mix and match drug and antenna to create drug release systems with 
preassigned wavelength triggers. For example, 780 nm illumination of erythrocytes 
containing the DyLight800 antenna (22) and the surface anchored drug 17 liberates Col, 
which rapidly enters co-incubated cells leading to the loss of microtubule integrity (Figure 
5c,d). Additionally, the presence of the Cy7 antenna (21) triggers the release of Mtx from 
surface-moored 16 at 725 nm. The liberated Mtx rapidly engages the dihydrofolate receptor 
in co-incubated cell lines. These studies establish that phototherapeutics assemble on the 
surface of carrier cells, tissue-penetrating wavelengths trigger drug release, and the 
wavelength of release is easily assigned. Furthermore, drug loading is not limited to cell 
surfaces on carrier cells but can be introduced into and photochemically released from both 
endosomes and the cytoplasm of cell carriers.56 For example, we have also successfully 
released drugs from neural stem cells,57 which display a pronounced ability to migrate to 
glioblastoma cells in vitro and tumors in vivo.58
5. ALKYL-Cbl-MEDIATED PHOTOPOLYMERIZATION OF HYDROGELS
Phototherapeutics, as broadly defined, are not just limited to the light-triggered release of 
drugs from cells or nanoparticles. A case in point are hydrogels, which have generated 
considerable biomedical interest in drug delivery and tissue engineering.4 These networks of 
cross-linked hydrophilic polymers mimic the softness and water content of natural tissue and 
serve in a number of capacities, including as scaffolds for implanted cells for use in tissue 
regeneration. The least invasive method of introduction is via injection of a viscous solution 
of pre-hydrogel and cargo (drug, cells, etc.) followed by gelation to create a spatially well-
defined depot at the treatment site. This approach has the advantages that the (1) cargo is 
well dispersed throughout the hydrogel, (2) introduction of the hydrogel/cargo into the 
patient is simple, and (3) the low viscosity solution fills the diseased site and thus easily 
assumes an appropriate shape upon gelation. Transition from a viscous solution to a spatially 
discrete hydrogel is triggered by a number of methods, including photopolymerization. 
Photocross-linking of acrylated biopolymers with photoinitiators is typically conducted with 
α-hydroxyphenyl ketones, such as Irgacure 2959 (λmax < 350 nm). However, these short 
wavelengths limit curing depth and efficacy.59
We developed a long wavelength photopolymerization hydrogel strategy (Scheme 2) that 
bears resemblance to the C–Co homolysis drug delivery approach outlined in Scheme 1.51 
Both approaches use antennas to capture long wavelength light to induce C–Co homolysis. 
However, the drug-linked radical intermediate in Scheme 1 is rapidly quenched, generating a 
freely diffusible cell-permeable drug. By contrast, the ethyl radical in Scheme 2 is formed in 
the presence of high concentrations of acrylated monomers or biopolymers, inducing 
polymerization and gelation.
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The green light absorbing (520 nm) ethyl-Cbl 14 and its red light absorbing (660 nm) 
counterpart 15 undergo photolysis at the anticipated wavelengths with high quantum yields, 
forming identical ethyl radicals.51 Both 14 and 15 promote polymerization of acrylic acid, 
acrylamide, N-isopropylacrylamide, hydroxyethyl acrylate, and PEG–monoacrylate upon 
illumination at 520 nm (Figure 6). However, only 15 supports photopolymerization at 660 
nm. In addition, live cells are easily encapsulated in a phototriggered hydrogel derived from 
PEG-diacrylate and the photoinitiator (i.e., 14 or 15). The photophysical properties 
associated with wavelength-assigned alkyl-Cbls could prove useful for cell implantation, in 
conditions ranging from the replacement of damaged cartilage to the treatment of 
glioblastoma.
6. CONCLUSIONS AND PERSPECTIVES
We have found that vitamin B12 can be used to create phototherapeutics that respond to 
wavelengths throughout the visible spectrum, from the edge of the UV to the NIR. 
Furthermore, the ability to preassign activation wavelengths to phototherapeutic-B12 
conjugates, using commercially available fluorophores, confers extraordinary and 
unprecedented flexibility relative to other photoactivatable constructs. The consequences of 
investigator-designated wavelength triggers range from creating phototherapeutics with 
desired photorelease characteristics to enabling wavelength-specific communication with 
individual prodrugs in a phototherapeutic mixture. The latter potentially permits sequential 
delivery of multiple drugs with unmatched temporal precision. Furthermore, the advantages 
of the fluorophore-as-an-antenna technology are not limited to the important function of 
receiving wavelengths throughout the optical window of tissue. The extinction coefficient of 
fluorophores (e.g., Cy5 250 000 M−1 cm−1 at 650 nm) are commonly more than an order 
magnitude greater than the molecule undergoing photocleavage (e.g., CH3CH2-Cbl 8275 
M−1 cm−1 at 520 nm),51 thereby dramatically enhancing the photon capturing ability of the 
molecular construct. The latter, in combination with recent extraordinary advances in the 
development of light-emitting devices,60,61 could prove pivotal in the challenging opaque 
environment of deep tissue. In addition, the quantum yields of photorelease are good relative 
to other photochemical processes (>5%).51 We do note that the mechanism by which 
fluorophore-mediated long wavelength capture leads to C–Co bond homolysis (energy 
transfer versus electron transfer?) remains unresolved. More significantly, in vivo studies 
will ultimately determine whether the biomedical implications of B12-dependent 
phototherapeutics, which range from high-resolution spatiotemporal drug delivery to tissue 
remodeling, are fully realized. These studies are in progress.
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Photosurgery in the 24th century? Wavelength-modulated illumination at the base of the 
brain triggers a series of surgical procedures to repair a traumatic brain injury. Photo Still 
from Star Trek: Voyager—Courtesy of CBS Television Studios.
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Light-induced (650 nm) translocation of BODIPY 650 in HeLa cells.43 (a) BODIPY–Cbl, 7, 
before photolysis. (b) Endosome visualization as revealed by an endosomal marker. (c) 
Overlay of panels a and b. (d) BODIPY–Cbl after photolysis. (e) Mitochondrial visualization 
as revealed by a mitochondria marker. (f) Overlay of panels d and e. Reproduced with 
permission from ref 43. Copyright 2014 John Wiley & Sons, Inc.
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Light-triggered cAMP-Cbl (6)-mediated rearrangement of actin cytoskeleton in REF52 
cells.43 Cells were exposed to 6, illuminated at 530 nm, and stained to visualize the actin 
stress fibers: (a) no treatment, media alone; (b) cell-permeable cAMP derivative as a positive 
control; (c) 6, no illumination; (d) 6 with illumination. Reproduced with permission from ref 
43. Copyright 2014 John Wiley & Sons, Inc.
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Self-assembly of a functional light-responsive drug release array on the surface of 
erythrocytes.44 Lipidated fluorophores serve as antennas, capturing the desired wavelength, 
which is then used to mediate drug release. The mechanism of “energy transfer” from 
antenna to drug–Cbl is currently under investigation. Reproduced with permission from ref 
44. Copyright 2014 John Wiley & Sons, Inc.
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Impact of the light-triggered release of drugs from erythrocyte carriers on co-incubated 
cells.44 (a) HeLa cells incubated (in the dark) in the presence of erythrocytes containing the 
Dex conjugate 18 and the Cy5 antenna 19. HeLa cells are stained for the Dex receptor, GRα, 
which is cytoplasmic in the absence of Dex. (b) Illumination at 650 nm releases Dex from 
erythrocytes, which enters HeLa cells, binds to GRα, and induces nuclear localization. (c) 
HeLa cells incubated (in the dark) in the presence of erythrocytes containing the Col 
conjugate 17 and the DyLight antenna 22. HeLa cells are stained for microtubules. (d) 
Illumination at 780 nm releases Col from erythrocytes, which enters HeLa cells and binds to 
and depolymerizes microtubules. Reproduced with permission from ref 44. Copyright 2014 
John Wiley & Sons, Inc.
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Light-triggered gelation of (a) acrylamide and bis-(acrylamide) or (b) PEG-monoacrylate 
and PEG-diacrylate in the presence of 14 (top) or 15 (bottom).51 Following treatment (dark, 
520, 660, or 730 nm), samples were inverted to visually assess gelation. Reproduced from 
ref 51. Copyright 2015 American Chemical Society.
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Structure of Vitamin B12 (R = CN, CH3, Adenosyl), 1, Shown in Full (left) and Schematic 
Forms (right)a
aPhotohomolysis of alkyl-Co(III)Cbl derivatives (R = alkyl) at wavelengths absorbed (330–
560 nm) by the corrin ring furnish the Co(II)Cbl, 2, and Alkyl Radical Intermediates (R•).
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Photohomolysis of 14 or 15 at Wavelengths 520 or 660 nm, respectively, Generates an Ethyl 
Radical, Which Triggers Hydrogel Formation in the Presence of Cells
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Wavelength-Distinguishable Photoresponsive Moieties 3–534
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Cbl-Linked cAMP (6), BODIPY (7), and Dox (8)43a
aPhotolysis generates a membrane permeable bio-active agent (exemplified by the 
conversion of 6 to a cAMP derivative).
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Photohomolysis of Fluorophore-Cbl Conjugates Where the Fluorophores Serve as Antennas 
To Capture 546 nm (9), 646 nm (10), 700 nm (11), and 777 nm (12) Wavelengths43a
aFluorophores appended to the ribose hydroxyl of Cbl likewise serve as antennas for 
wavelengths in the 650–800 nm realm, which trigger the release of Co-linked ligands 
(confirmed by LC-MS) as exemplified by release of the adenosyl moiety in 13.
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Photohomolysis (520 nm) of 14 Is Compromised by Filters Mimicking Skin Types That 
Vary from Light to Dark;51 By Contrast, 15 Undergoes Photohomolysis at 660 nm in the 
Presence of All Skin Types
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Drug–Cbl–Lipid Conjugates (16–18) and Lipidated Fluorophores (19–22) Self-Assemble on 
the Surface of Erythrocytes to Create Functional, Photoresponsive, Drug-Releasable 
Arrays44
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